An Associated Press report examines the growing political interest in psychedelic therapies within the federal government, including comments from Health and Human Services Secretary Robert F. Kennedy Jr. supporting expanded clinical research into substances such as MDMA and other psychedelics. The discussion follows a recent FDA setback for MDMA-assisted therapy and highlights debate among researchers, policymakers, and clinicians about how quickly psychedelic treatments should move through the approval process.
The article also notes increased momentum at the state level, particularly Texas’ $50 million investment in ibogaine research to study its potential for treating opioid addiction, PTSD, and related conditions. Advocates, including former Texas Governor Rick Perry and leaders from Americans for Ibogaine, argue that state-led initiatives could help advance scientific research into the compound, while researchers emphasize the need for rigorous clinical trials to fully evaluate its potential benefits and risks.